Key facts
- Qubit Pharmaceuticals’s last known valuation is $48.1M (Jun 2022).
- It has raised $28.7M; the latest was Later Stage VC ($2.3M) in Oct 2025.
- Notable investors include European Innovation Council, La French Tech, XAnge, Omnes Capital, Audacia — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Qubit Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Qubit Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Qubit Pharmaceuticals
Developer of a drug discovery simulation platform designed to reduce the cost and length of preclinical drug development. The company's platform uses proprietary force field models and molecular dynamics calculations, performs virtual screening and visualization to find valuable candidates, enabling biopharmaceutical companies to get support in their research and development by accelerating drug discovery with quantum physics.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2020
- Employees
- 71
- Website
- qubit-pharmaceuticals.com/
- Ownership
- Privately Held (backing)
Qubit Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Qubit Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Qubit Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.